We want to see if a medicine called AZD2014 is effective and safe to use when treating 30 patients with relapsed or refractory Diffuse Large B Cell Lymphoma. In six patients we will also add the medicine Rituximab to AZD2014 to see if this can be done without increasing the toxicity of AZD2014.
AZD2014 will be given as tablets to be swallowed twice a day on days 1 and 2 of every week. Rituximab will be infused into the blood vessels on day 1 of every 28 days (once every 4 weeks) for a maximum of 6 cycles.
Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible
| Chief Investigator: |
Dr Graham Collins |
| Sponsor: |
The University of Birmingham |
| Funders: |
Bloodwise (TAP) |
| Disease Site: |
Diffuse Large B cell Lymphoma |
| Trial Type: |
Clinical Trial of an Investigational Medicinal Product |
| Status: |
Follow-up |
| UKCRN Study ID: (if applicable) |
19208 |
| Open to new sites? |
No |
| Recruitment start date: |
19-Oct-2015 |
| Recruitment end date |
25-Apr-2017 |
| CRCTU Trial Management Team: |
Haematology |
| Trial E-mail Address: |
Torch@trials.bham.ac.uk |